AC
VRTX icon

Alexandria Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Alexandria Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-74
Closed -$11K – 521
2017
Q3 		$11K Buy
74
+4
+6% +$602 ﹤0.01% 411
2017
Q2 		$9K Buy
70
+9
+15% +$1.08K ﹤0.01% 438
2017
Q1 		$7K Buy
61
+5
+9% +$440 ﹤0.01% 463
2016
Q4 		$4K Buy
56
+9
+19% +$732 ﹤0.01% 503
2016
Q3 		$4K Buy
47
+7
+18% +$662 ﹤0.01% 516
2016
Q2 		$3K Buy
40
+6
+18% +$518 ﹤0.01% 534
2016
Q1 		$3K Buy
34
+18
+113% +$1.63K ﹤0.01% 540
2015
Q4 		$2K Buy
+16
New +$1.93K ﹤0.01% 604
2014
Q3 		– Sell
-29
Closed -$3K – 596
2014
Q2 		$3K Sell
29
-21
-42% -$1.47K ﹤0.01% 511
2014
Q1 		$4K Hold
50
– – ﹤0.01% 489
2013
Q4 		$4K Sell
50
-27
-35% -$1.88K ﹤0.01% 500
2013
Q3 		$6K Buy
77
+7
+10% +$557 ﹤0.01% 437
2013
Q2 		$6K Buy
+70
New +$5.16K ﹤0.01% 460

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Alexandria Capital's VRTX Position: Q4 2017 in Review

Alexandria Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 74 shares — an estimated $11K sold.

Alexandria Capital first reported a position in VRTX in Q2 2013 and held it in 13 quarters. The position peaked at $11K in Q3 2017. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

  • Alexandria Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Alexandria Capital sold 74 Vertex Pharmaceuticals shares in Q4 2017, an estimated $11K.
  • Alexandria Capital first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Alexandria Capital's Vertex Pharmaceuticals position peaked at $11K in Q3 2017.
  • 644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on Alexandria Capital's 13F filing for Q4 2017, filed 9 Feb 2018.